Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

CMT-dos > Leukemia > Flashcards

Leukemia Flashcards

1
Q

leukemia

definition

A

Leukemia is a malignancy of the blood
Increased production and proliferation of abnormal leukocytes and leukocyte precursors in the bone marrow and in circulating blood

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

lines of leukemia

myoblasts should stay in bone marrow and not be in circulation
A
  • Myelogenous leukemias arise from the granulocyte
    (neutrophils, eosinophils, basophils and monocytes), erythrocytes and platelets.
    Acute Myeloid Leukemia (AML) and Chronic Myeloid Leukemia (CML)
  • Lymphocytic leukemias involve the lymphocyte lineage
    T and B lymphocytes.
    Acute Lymphocytic Leukemia (ALL) and Chronic Lymphocytic Leukemia (CLL)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

leukemia

patho

A

Uncontrolled/dysfunctional multiplication of one or more types of leukocytes, resulting in the presence of undifferentiated, immature, nonfunctional cells in the bone marrow.

Malignant transformation occurs at different levels of cell differentiation

Acute leukemias
High proportion of immature and nonfunctional cells
Blast cells

Chronic leukemias
Higher proportion of mature cells
Some of these cells have reduced function

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Acute vs chronic leukemia

A

Acute leukemias
High proportion of immature and nonfunctional cells
Blast cells

Chronic leukemias
Higher proportion of mature cells
Some of these cells have reduced function

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Sub-types of Leukemia

A

chronic leukemias tend to have leukocytosis (increase in leukocytes)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Chronic Lymphocytic Leukemia (CLL)

General

A

aka small lymphocytic lymphoma (SLL)

CLL/SLL is considered one disease with different manifestations
CLL = disease primarily manifesting in the blood
SLL = disease involvement primarily nodal

  • Characterized by the progressive accumulation of a population of small mature B lymphoctyes

Most common form of adult leukemia
Median age of diagnosis is 70
CLL has a strong familial predisposition
No definitive causative factors are associated with CLL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

CLL/SLL

Clinical manifestations & Physical Examination

A

Asymptomatic (with incidental findings on a CBC)
Fatigue
Dyspnea on exertion
Increased incidence of infections
Lymphadenopathy
Splenomegaly
“B” symptoms – Fevers, night sweats, weight loss
Appetite loss
Unusual bruising/bleeding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

CLL/SLL

Workup/Diagnosis

A

CBC with differential
Leukocytosis
Lymphocytosis (high)
Anemia
Thrombocytopenia
Peripheral smear – “smudge cells” - classic for CLL
Hypogammaglobulinemia
Flow cytometry immunophenotyping
Increased number of circulating lymphocytes that are monoclonal B cells expressing CD5 antigen
Cytogenetic studies (FISH, etc.)
Lymph node biopsy
CT scans
+/- bone marrow biopsy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

CLL

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

CLL

factors to consider for Tx

A

May develop
Autoimmune hemolytic anemia
Autoimmune thrombocytopenia
Initiation of therapy dependent on several factors
Lymphocyte doubling time- looking at CBCs to see how fast WBC count doubles.
Disease stage
Age
Comorbidities
Symptoms
ACFatigue
Symptomatic lymphadenopathy
Therapy goal in most patients is palliation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

CLL

Tx

A

Early stage
Observation

Targeted biologics- not chemo
Anti-CD20 agent (Rituximab{Rituxan}, Obinutuzumab{Gazyva}) + one of the following:
Tyrosine kinase inhibitor:
Ibrutinib (Imbruvica)
BCL-2 targeted agent:
Venetoclax (Venclexta)

Curative therapy (allogeneic transplant) is reserved for younger patients with aggressive symptomatic disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Ibrutinib (Imbruvica)

general

A

BTK Inhibitor
Inhibits Bruton tyrosine kinase leading to inhibition of malignant B cell proliferation

Dosing: 420mg PO daily
Caution with CYP3A inhibitors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Ibrutinib (Imbruvica)

Side effects

A

Side effects:
Lymphocytosis (increases by 2-3x before it goes down)
HTN
Cardiac arrhythmias
Rash
Infections
Bleeding risk in conjunction with Warfarin (Coumadin)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Venetoclax (Venclexta)

general

A

BCL-2 Inhibitor
Inhibits B-cell lymphoma 2 protein leading to restoration of apoptosis
Dosing: 400mg PO daily (slow titration to max dosing)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Venetoclax (Venclexta)

side effects

A

Side Effects:
Tumor lysis syndrome
May need hospitalization for first cycle
Neutropenia
Infection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Tumor Lysis Syndrome

general and clin man

A

Risk in hematologic and rapidly proliferating solid tumor malignancies
Caused by rapid release of cellular contents

With impaired breakdown:
Hyperuricemia
Acute kidney injury
Hyperkalemia
Hyperphosphatemia

Clinical manifestations
Nausea/vomiting
Seizures
Arrhythmias
Death

17
Q

tumor lysis syndrome

tx

A

Prevention
Baseline uric acid level

Allopurinol 100mg PO daily-TID starting before chemotherapy initiation
Inhibits xanthine oxidase (prevents conversion to uric acid)

Rasburicase IV weight dosing IV x 7 days
Converts uric acid to allantoin, inactive metabolite easily renally excreted
Avoid with G6PD deficiency

Aggressive IV hydration

18
Q

Chronic Myeloid Leukemia (CML)

general

A

Malignancy driven by the BCR-ABL-1 gene product (active tyrosine kinase)
Translocation between the long arms of chromosomes 9 and 22
Philadelphia Chromosome (Ph)
15% of all cases of leukemia
Median age at diagnosis is 55yrs
No familial associations
Usually a primary leukemia

19
Q

CML

Clin man

A

Typically asymptomatic with incidental findings on a CBC
Fatigue, malaise
Weight loss
Early satiety
LUQ pain
Bone pain
Night sweats
Thrombotic or vasoocculsive events
Splenomegaly (20-70%)

20
Q

CML

phases

A

90% of patients present in the indolent or chronic phase
Chronic phase
Accelerated phase
Blastic phase

21
Q

CML

signs of turning into acute (AML)

A

Signs of transformation to AML
Leukocytosis resistant to therapy
Increasing anemia
Increasing blasts
Constitutional symptoms

22
Q

CML

Dx

A

CBC with differential
Leukocytosis (10-500) :
Left shift with many neutrophils
Bands
Myelocytes
Blasts
Elevated basophils

Thrombocytosis
Anemia in 1/3 of patients
CMP
Uric acid
Bone marrow biopsy with cytogenetic analysis
FISH testing (identifies % of Ph chromosome)
PCR for BCR-ABL gene

23
Q

CML

Tx

A

Response to treatment is gauged by quantitative PCR levels
Tyrosine Kinase Inhibitor (TKI) therapy
Imatinib (Gleevec) 1st drug
30% reach major molecular response in 1 yr
Nilotinib (Tasigna)
71% MMR in 1 yr

Allogeneic transplant if fails TKI or in accelerated/blast phase

Leukopheresis
Symptoms from hyperleukocytosis
Total leukemia blood cell count greater than 50 x 109/L (50,000/microL) or 100 x 109/L (100,000/microL)
Symptoms of decreased tissue perfusion
Medical emergency!

24
Q

Side effects of TKIs

A

Drug rashes
QTc prolongation
Edema
Cytopenias
Diarrhea

25
Q

Acute Lymphocytic Leukemia (ALL)

general

A

Malignancy defined by the proliferation and accumulation of clonal blast cells (B- or T- lymphocyte progenitor) in the marrow
Most common in children
Median age at diagnosis: 15
57.2% < 20 at age of diagnosis
26.8% of cases are ≥45 at age of diagnosis
11% diagnosed at age ≥ 65yrs
75%-80% of acute leukemias in children
Risk factors:
Age >70
Exposure to chemo or radiation therapy
Genetic disorders
Down’s syndrome
rare = neurofibromatosis, Klinefelter, Fanconi, etc.
**Philadelphia chromosome and BCR-ABL1 fusion*

26
Q

ALL

clin man

A

Presentation can be highly variable
Approx 50% patients present with fever
Fatigue and lethargy
> 25% of patients (esp. young children) may have a limp from bone pain or arthralgia
Arthralgia and bone pain less severe in adults
Occasionally, life-threatening infection or bleeding
Lymphoblasts can accumulate in various extramedullary sites
Meninges, testes, thymus, liver, spleen, and lymph nodes

27
Q

ALL

Labs/ Dx

A

CBC with differential,
Anemia, neutropenia, and thrombocytopenia common (All cell lines will be down)
Blasts
(90% of patients have circulating blasts at diagnosis)
CMP
LDH
Correlates with tumor burden
Uric acid, phosphorus, calcium, (tumor lysis syndrome), coagulation studies
Bone marrow biopsy (>20% lymphoblasts)

Lumbar puncture
Leukemic blasts can be identified in as many as 33% of pediatric patients and approx. 5% of adult patients at diagnosis of ALL
most of these patients lack neurologic symptoms

Echocardiogram
Cardiac risks from chemotherapy

28
Q

ALL

Chemo phases

A

Treatment consists of three standard phases:
Induction
Consolidation
Maintenance

29
Q

ALL

Tx

A

Needs CNS-directed therapy
In adult ALL, long-term disease-free survival rates:
35 to 50% with chemotherapy alone
45 to 60% with allogeneic transplantation
Most relapses typically occur during treatment or within the first 2 years after completion
CAR-T therapy is improving survival

30
Q

ALL

CAR-T therapy

A
  • Chimeric antigen receptor T cells
  • A newer immunotherapy for relapsed refractory ALL in age <25yrs, also some types of lymphomas (in adults)
  • Patient’s own T cells are removed and genetically modified to express a receptor programmed to fight against specific cells (in this case those that express CD19, present on the B cell precursor in ALL)
  • T cells are infected using a virus carrying a specific CAR
  • The modified T cells are then infused back into the patient
  • Response rates up to 90%
    Unfortunately, frequent relapses
31
Q

Acute Myeloid Leukemia (AML)

epidemiology and eti

A

Malignancy characterized by infiltration of bone marrow, blood, and other tissues by proliferative, clonal, undifferentiated cells (myeloid origin)
Incidence increases with age
Median age at diagnosis: 65

Risk factors:
Benzene exposure
Smoking
Exposure to petroleum products, paint, embalming fluids, ethylene dioxide, herbicides, pesticides
Certain genetic syndromes
Prior chemotherapy
Underlying bone marrow disorder

32
Q

AML

Clin Man

A

Fatigue, weakness
Anorexia
Weight loss
Fever (10%)
Easy bleeding/bruising (5%)
Occasionally bone pain
Splenomegaly,
Hepatomegaly
Lymphadenopathy
Sternal tenderness

33
Q

AML

Workup/Dx

A

CBC with differential
Anemia
Thrombocytopenia
Mild leukocytosis or leukopenia
CMP, LDH, uric acid, phosphorus, coagulation studies
Peripheral smear
Auer rods on the peripheral smear
Bone marrow biopsy (20% blasts)
Flow cytometry
Cytogenetic analyses (karyotype +/- FISH), Molecular analyses, HLA typing
These studies are essential because of the prognostic value specific mutations hold
+/- brain imaging
+/- Lumbar puncture
Echocardiogram

34
Q

Subtypes of AML

Acute Promyelocytic Leukemia (APL)

A

Subtype of AML that must be quickly recognized and promptly treated

Disseminated Intravascular Coagulation
Significant GI bleeding, intrapulmonary hemorrhage, ICH
Treatment can rapidly reduce DIC complications

ATRA (all-trans retinoic acid) + ATO (arsenic trioxide)
Without treatment, APL has median survival of < 1month
With modern therapy, APL is associated with the highest cure rates

35
Q

AML

Tx and complications

A

Treatment consists of
Induction chemotherapy (to induce remission)
Consolidation
Transplant or some form of maintenance therapy
Chemotherapy treatment has similar complications/risks as in ALL

36
Q
A

CMT-dos (95 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions